Clinical TrialJul 7, 2026, 08:01 AM
SAB Biotherapeutics Funds New T1D Clinical Study for SAB-142
AI Summary
SAB Biotherapeutics announced that Breakthrough T1D has awarded a grant to support the PRISE-hATG clinical study, which SAB BIO will co-fund. This study will evaluate SAB-142, a fully human anti-thymocyte immunoglobulin (hATG), in patients with Stage 3 Type 1 Diabetes (T1D) who are 100 days to 2 years from diagnosis. The PRISE-hATG study aims to assess SAB-142's ability to preserve endogenous C-peptide and modulate immune responses, expanding the clinical evaluation of the drug beyond the earliest stages of the disease.
Key Highlights
- Breakthrough T1D awarded a grant to support the PRISE-hATG clinical study.
- SAB Biotherapeutics will co-fund the PRISE-hATG study for SAB-142.
- PRISE-hATG evaluates SAB-142 in Stage 3 T1D patients 100 days to 2 years post-diagnosis.
- The study aims to preserve endogenous C-peptide and modulate immune responses.
- PRISE-hATG complements the ongoing Phase 2b SAFEGUARD trial for SAB-142.
Price Impact
More from SABS